ZANOPRIMA-LIFESCIENCES
11.10.2021 12:15:06 CEST | Business Wire | Press release
Zanoprima Lifesciences (www.zanoprima.com ) (https://www.linkedin.com/company/zanoprima/ ) a UK based company, announced commercial production of its high purity synthetic (S)-Nicotine (SyNic) using a revolutionary patented process that does not involve the use of tobacco or any synthetic racemic mixture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005296/en/
This is a landmark development for the trillion-dollar tobacco industry and its 1.3 billion consumers as it heralds the arrival of a superior, substantially lower-risk, cost-effective, and greener alternative to a global industry that is arguably the single biggest avoidable cause of death globally.
Zanoprima has developed and patented the process to manufacture high purity (typically 99.9%), synthetic (S)-Nicotine (SyNic) for commercial use that is free of TSNA (tobacco-specific Nitrosamines), toxins, carcinogens, odour, and harsh taste. Zanoprima offers the entire range of products including SyNic (S)-Nicotine Bitartrate (Nicotine Bitartrate Dihydrate), SyNic (S)-Nicotine polacrilex resin/Nicotine resinate and its novel proprietary (S)-Nicotine complex.
SyNic (S)-Nicotine conforms to and exceeds European Pharmacopeia (EP) and United States Pharmacopeia (USP) specifications. “Green Chemistry” principles compliant production process minimizes the environmental impacts of nicotine production. Applications include:
SyNic Protonated (S)-Nicotine e-liquid for e-cigarettes is without any potentially harmful ingredients such as organic acids and propylene glycol. It is pure, stable and has a long shelf life. E-cigarettes that use SyNic offer a smooth taste and enhanced nicotine experience, a distinct advantage given the nicotine limit guidelines/rules in e-liquids in the EU and other geographies.
Znus: Tobacco-free white snus is completely sodium and tobacco free, delivering a smooth taste without the characteristic odour and harshness of natural nicotine. It has an instant burst followed by sustained release as desired by the traditional Snus users.
Next-gen chewing gum and lozenges that are sodium free offer unique characteristics, providing an instant burst and sustained release of nicotine that users seek. These gums and lozenges contain a new proprietary nicotine complex with superior bioavailability and taste.
Forthcoming launches: Tobacco free heated nicotine products unlike existing tobacco-based Heat Not Burn products and skin friendly transdermal patches for Alzheimer’s and dementia.
Global Patents: Zanoprima owns patent applications or registration for its revolutionary manufacturing process in all major geographies including United States, Europe, Great Britain, Australia, China, India, and others.
As a responsible synthetic nicotine (SyNic) manufacturer Zanoprima will distribute SyNic in strict compliance with regulations in each of its markets, globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005296/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpZira, Inc. Welcomes Scott Thielman, PhD, as Vice President of Product Development30.6.2026 13:17:00 CEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced that Scott Thielman, PhD, PE, has joined the company as Vice President of Product Development, effective May 1, 2026. Dr. Thielman brings a unique connection to OpZira’s origins. As Chief Technology Officer of Product Creation Studio, he directed the product development of LumiThera’s Valeda® Light Delivery System - the breakthrough photobiomodulation therapy for dry age-related macular degeneration whose acquisition by Alcon led to the creation of OpZira. His involvement with Valeda gives him firsthand knowledge of the science, clinical vision, and engineering decisions that shaped the technology platform from which OpZira was born. For more than 25 years, Dr. Thielman has directed the development of dozens of FDA-cleared medical devices across ophthalmology, neurostimulation, dermatology, urology, and surgical instrumentation, with partners including Olympus
L&T Technology Services Launches Ainfonix™ 4.0 to Unlock Engineering Intelligence Across Process Industries30.6.2026 12:45:00 CEST | Press release
The enterprise AI platform turns millions of engineering artifacts that run a plant into accurate, decision-ready data, delivering up to 85% extraction accuracy and full, audit-ready traceability L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of Ainfonix™ 4.0, a next-generation Engineering Intelligence platform for process industries. Unveiled at EI Live, LTTS’ flagship event that brings together analysts, industry leaders and engineering experts, Ainfonix™ 4.0 marks an important step in the company’s Enterprise AI and Engineering Intelligence strategy. As industrial enterprises accelerate AI adoption, decades of engineering knowledge remain trapped in fragmented drawings, specifications and technical records across disparate systems. Without trusted and accessible engineering data, organizations struggle to realize the full value of AI, automation and digital transformation
Klick Health Acquires Oxford PharmaGenesis, Bringing Together Unsurpassed Scientific-to-Commercial Capabilities for Life Sciences Clients30.6.2026 12:03:00 CEST | Press release
Bonded by breakthroughs and a laser focus on their people and clients, leading independent agencies join forces to deliver accelerated commercial success through broadened medical affairs and communications, market access, and RWE/HEOR offerings; the most advanced degree holders; expanded global reach; and the best workplace culture around Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America. Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick's strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma30.6.2026 12:00:00 CEST | Press release
Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFSMANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusionsFull results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibitor-based chemotherapy-
Hytera Debuts SC700 Smart 4G Body Camera at CCW 202630.6.2026 11:30:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, officially debuted its SC700 Smart 4G Body Camera at Critical Communications World (CCW) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630283236/en/ Hytera's latest SC700 Smart 4G Body Camera Public safety operations are increasingly moving toward real-time, connected workflows, where communication, video, and situational awareness are integrated to support a faster and more coordinated response in the field. The SC700 is designed to support this shift. It enables live video, location sharing and push-to-talk communication, helping connect frontline officers with control rooms. Integrated with Hytera HyTalk PoC System, it also supports communication across broadband and PMR users to improve coordination across teams. It also features Intelligent Scene Aware, which can detect abnormal situations such as man down, inactivity, or
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
